Colorectal - oncology - SA Health Approved Cancer Chemotherapy Protocol Register
Adjuvant and neoadjuvant
| Protocol | Administration at chemotherapy unit level | Review Date |
|---|---|---|
| Colorectal adjuvant capecitabine | Low | February 2023 |
| Colorectal adjuvant CAPOX (XELOX) (Capecitabine and Oxaliplatin) The SA Health Cancer Drug Committee has approved this protocol for the additional indication: Neoadjuvant therapy prior to definitive surgery |
Medium | February 2023 |
| Colorectal adjuvant de Gramont (modified) (fluorouracil and leucovorin) | Low | February 2023 |
| Colorectal adjuvant FOLFOX6 (Modified) (fluorouracil leucovorin oxaliplatin) The SA Health Cancer Drug Committee has approved this protocol for the additional indication: Neoadjuvant therapy prior to definitive surgery |
Medium2 | February 2023 |
| Colorectal adjuvant QUASAR (Modified) fluorouracil leucovorin weekly | Low | February 2023 |
Metastatic
Anal
| Protocol | Administration at chemotherapy unit level | Review Date |
|---|---|---|
| Anal advanced cARBOplatin and PACLitaxel | Medium | February 2022 |
| Anal definitive cISplatin and fluorouracil chemoradiation | Medium2 | August 2021 |
| Anal definitive mitomycin and capecitabine chemoradiation | Medium | February 2021 |
| Anal definitive mitomycin and fluorouracil chemoradiation | Medium2 | February 2023 |
Rectal
| Protocol | Administration at chemotherapy unit level | Review Date |
|---|---|---|
| Rectal locally advanced capecitabine chemoradiation | Medium | August 2021 |
| Rectal locally advanced fluorouracil (protracted Infusion) chemoradiation | Medium2 | February 2023 |
| Rectal Neoadjuvant/adjuvant CAPOX – Interim “Radiotherapy may be scheduled before or after systemic cancer therapy as appropriate to individual patient treatment plan” (for information on this protocol please contact the SA Health Cancer Drug Committee) |
Medium | November 2021 |
| Rectal Neoadjuvant/adjuvant FOLFOX – Interim “Radiotherapy may be scheduled before or after systemic cancer therapy as appropriate to individual patient treatment plan” (for information on this protocol please contact the SA Health Cancer Drug Committee) | Medium2 | November 2021 |
Notes
- Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
- Fluorouracil pumps may be connected/disconnected at low-risk units
- Non-formulary drug included in the protocol
- Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.
